While the results raise the possibility that APOE-linked metabolic pathways contribute to neuropathic risk, they remain exploratory and require independent confirmation, given their cross-sectional design, their focus on a single population (Lebanese), and the inability to establish temporal relationships between genotype, dyslipidemia, and neuropathy. The gene discussed is APOE; the disease is metabolic syndrome.